please check if there is any lab or university where we might have these tests, it wil be very difficult to see them around soon since they show how poor and useless are expensive Nucs produced by US drug makers (and thanksfully copied in india)
chinese research (and asian in general) is helping very much in the study of hbv.this study is very very important and we should find labs to make this test like they did for CFS patients where they made a specialized lab by donations
The main target organ of HBV
infection is the liver; however, recent studies revealed
that the virus has extensive reservoirs of extrahepatic
HBV proteins and nucleic acids have been
found in a number of non-hepatic tissues or cells,
including lymph nodes, spleen, bone marrow, kidney,
colon, stomach, periadrenal ganglia, skin, thyroid,
pancreas, testis, ovaries, brain, heart, lung, peripheral
blood mononuclear cells (PBMC) and endothelial
Unlike the liver, the replication of
HBV in these non-hepatic cells is unclear. Because
cccDNA is a template for the replication of HBV, the
presence of cccDNA in PBMCs and marrow mononuclear
cells (MMNCs) demonstrates not only the infection of
PBMC and MMNC by HBV, but also the replication of
HBV in these cells.
Several methods are currently available to detect HBV
cccDNA in liver tissues
and increasing attention is
being paid to the presence of cccDNA in PBMCs. In the
present study, a nested real-time quantitative polymerase
chain reaction (RT-PCR) protocol was modified to detect
cccDNA in both PBMCs and MMNCs. This method was
used to evaluate the effectiveness of antiviral drugs in the
clearance of HBV and monitor therapeutic efficacy.
In the treatment of hepatitis B, only the clearance of
template for HBV DNA replication (i.e., clearance of
cccDNA) can completely cure hepatitis B to achieve a
favorable outcome. In this study, we established a
high-sensitive nest real-time quantitative PCR assay for
detecting hepatitis B virus cccDNA in PBMCs and
MMNCs, which may serve as an invaluable tool for
detecting cccDNA in hepatitis B patients, evaluating the
severity of liver damage and the state of HBV infection,
selecting an appropriate treatment strategy, evaluating the
efficacy of antiviral drugs, indicating when to stop the
treatment, and predicting the prognosis.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.